

Gemini Stock Analysis Report

Based on the comprehensive analysis of the **AUROPHARMA.NS** technical and fundamental report (Reference Date: 2026-01-31), here is my assessment.

Step 1: Audit the Data

• Data Present:

- **Price Action:** Daily and Weekly candlestick charts (3-year history).
- **Trend Indicators:** EMA Clusters (20, 50, 200), Supertrend, and Bollinger Bands.
- **Momentum:** RSI, MACD, and Relative Strength (RS) against the Benchmark (CNXPHARMA).
- **Volume:** Volume moving averages and accumulation/distribution signals.
- **Fundamentals:** Quarterly and Annual revenue/profit growth metrics.

• Data Missing:

- **Order Book/Depth:** No Level 2 data to gauge immediate supply/demand walls.
 - **Institutional Activity:** Specific FII/DII buying/selling flows for the current month.
 - **Confidence Level: High.** The report provides a complete technical picture including multi-timeframe analysis (Weekly/Daily/15min) and crucial volatility metrics (squeeze analysis).
-

Step 2: Analyze the Setup

Price Structure & Trend:* **The Good:** The stock is attempting a recovery. It is currently trading at **INR 1207.70**, which is above the critical **200-day EMA (1160.29)**. Holding the 200 EMA is a classic sign of long-term trend support. Furthermore, price has recently reclaimed the 20 and 50 EMAs, which are bunching together-often a precursor to an expansion move.* **The Bad:** The daily **Supertrend is still Negative (Sell)** with a resistance value at **1219.86**. The stock is trapped between the support of the EMAs (1160-1175) and the resistance of the Supertrend (1220) and Upper Bollinger Band (1245).

Momentum & Volume:* **MACD:** Shows a **Bullish Crossover** and is rising, indicating shifting momentum to the upside on the daily chart.* **RSI:** At **58.30**, it is in neutral-bullish territory with room to extend before becoming overbought.* **Volume:** This is a concern. The current volume (8.12M) is below the 20-day average (11.88M). The rally lacks strong conviction from institutional buyers (low volume on up moves).* **Relative Strength:** The stock has an RS Score of **54/100**. It is a "Weakening Leader." While short-term RS (1 Month) is improving, it is not yet outperforming the Pharma sector significantly.

Fundamental Context:* Short-term fundamentals are weak (Revenue -7.03% QoQ, Net Income -8.71% QoQ), which explains the lack of explosive volume. The trade relies strictly on technical structure repair.

Step 3: Formulate the Recommendation

Verdict: NO (Wait for Confirmation)

Rationale: While the setup is promising because it held the 200 EMA, entering exactly at INR 1207 is risky. You are buying directly into overhead resistance (Daily Supertrend at ~1220 and Upper Bollinger Band at ~1245). Given the low volume, a rejection at 1220 is a distinct possibility.

Gemini Stock Analysis Report

As a positional trader, we need price to clear the "noise" and confirm the trend reversal.

Conditional Plan:

- **Condition to Buy: Daily Close above INR 1225.**
 - *Why:* This clears the Daily Supertrend resistance (1219.86) and confirms a breakout from the EMA compression zone.
- **Entry Price: INR 1225 - INR 1230** (On the retest or breakout candle).
- **Stop Loss: INR 1155** (Closing Basis).
 - *Why:* This is just below the critical 200 EMA (1160). If it loses the 200 EMA again, the intermediate trend is broken.
- **Take Profit: INR 1350** (Target 1) and **INR 1400** (Target 2).
 - *Why:* INR 1350 aligns with previous consolidation highs (visible on the page 2 chart) offering a ~10% upside.
- **Time Horizon:** 4-8 Weeks.

Risk/Reward Ratio: ~1:1.8 to 1:2.5 (depending on entry). This fits the criteria for an intermediate positional trade.

News & Analyst Targets

As a stock research analyst, I have compiled the latest news, brokerage updates, and analyst targets for **Aurobindo Pharma (AUROPHARMA)** as of the final week of January 2026.

1) Latest News for AUROPHARMA (Week of Jan 26-31, 2026)

- **Govt. Impressed Minimum Import Price (MIP) - Major Positive:** On **January 29, 2026**, the Directorate General of Foreign Trade (DGFT) imposed a Minimum Import Price on specific antibiotics to curb cheap imports.
 - **Penicillin-G:** MIP fixed at **\$24/kg** (approx. INR 2,216).
 - **Amoxicillin:** MIP fixed at **\$30/kg** (approx. INR 2,733).
 - **6-APA:** MIP fixed at **\$37/kg** (approx. INR 3,405).
 - **Impact:** This is a significant positive for Aurobindo Pharma's subsidiary, **Lyfius Pharma**, which has recently commissioned a large 15,000 MT Penicillin-G plant under the government's PLI scheme. The MIP acts as a floor price, protecting domestic manufacturing margins from dumping.
- **Share Price Surge & Clarification:** The stock surged approximately **6-8%** following the MIP news. In response to a query on significant volume movement, the company clarified to stock exchanges on **Jan 30, 2026**, that the rally was market-driven based on the public DGFT notification and not due to any undisclosed company information.
- **Upcoming Q3 Earnings:** The Board of Directors is scheduled to meet on **February 9, 2026**, to approve the un-audited financial results for the quarter ended December 31, 2025.
- **New Subsidiary:** On **Jan 23, 2026**, the company incorporated a new wholly-owned step-down subsidiary, **Aurobindo Pharma Philippines, Inc.**, to expand its footprint in the Southeast Asian market.

2) Brokerage Upgrades & Downgrades

- **ICICI Securities (Upgrade Target):** In a report dated **Jan 30, 2026**, the brokerage maintained its **BUY** rating and **raised** its target price to **INR 1,500** (from INR 1,350). They cite the new MIP policy as a key catalyst that could lift the gross margins of the Pen-G project to ~60% in FY27.

Gemini Stock Analysis Report

- **Motilal Oswal (Reiteration):** The firm reiterated its **BUY** rating with a target of **INR 1,430** on **Jan 30, 2026**, noting that the MIP implementation will aid the ramp-up of the PLI Pen-G project and support domestic manufacturing.
- **Macquarie (Maintain Underperform):** Contrasting the bullish view, Macquarie maintained an **Underperform** rating with a target of **INR 1,010**, remaining cautious despite the policy support.
- **MarketsMojo (Downgrade):** Earlier in the cycle (Dec 2025), the platform downgraded the stock from **Buy** to **Hold**, citing a balanced risk-reward profile at current valuations.

3) Other Impacting News (Direct & Indirect)

- **US FDA Observations (Negative Hangover):** The company is still dealing with regulatory observations from late 2025.
 - **Unit-IV (APL Healthcare):** Received **5 observations** (Form 483) following an inspection in mid-December 2025.
 - **Unit-V (Apitoria Pharma - API):** Received **3 observations** in December 2025.
 - **Analyst Note:** While the MIP news is a strong positive, the resolution of these FDA observations is critical for the seamless launch of future products in the US market.
- **PLI Scheme Traction:** The government's move to restrict imports validates the success of the Production Linked Incentive (PLI) scheme, directly benefiting Aurobindo as one of the few players with end-to-end capabilities (Pen-G -> 6-APA -> Amoxicillin).

4) Latest Analyst & Brokerage Targets

Below is the summary of the latest price targets released or reiterated in **January 2026**.

Brokerage / Firm	Rating	Target Price (INR)	Date / Status
ICICI Securities	BUY	1,500	Jan 30, 2026 (Raised from 1,350)
Motilal Oswal	BUY	1,430	Jan 30, 2026 (Reiterated)
Trendlyne Consensus	BUY	~1,350	Jan 31, 2026 (Avg. Estimate)
Macquarie	Underperform	1,010	Jan 30, 2026 (Maintained)
MarketsMojo	HOLD	N/A	Current Rating (Downgraded Dec '25)

Analyst Summary: The consensus view has shifted to a more **bullish** stance this week due to the government's policy intervention (MIP), which directly improves the profitability visibility for Aurobindo's massive new capex projects. However, regulatory compliance (FDA) remains a key risk to monitor.


Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1207.70

Generated: 2026-01-31 11:36

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUOPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.0/100
:	

== RS RATIOS ==:

1M RS:	1.059 [Leader]
3M RS:	1.113 [Leader]
6M RS:	1.123 [Leader]
1Y RS:	0.981 [Neutral]
:	




== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.981 (≤ 1.0)
✓ Performance Improving:	3M (+8.6%) > 6M (+7.6%)

Relative Strength Analysis: AUOPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1169.12
EMA 50:	1174.97
EMA 200:	1160.29
Trend Status:	Short-term Downtrend
Golden Cross Date:	2025-11-26 00:00:00+05:30
Golden Cross Price:	1227.40


AUROPHARMA.NS EMA Crossover Analysis



AUOPHARMA.NS - Bollinger Bands Summary

Current Price:	1207.70
Upper Band:	1245.56
Middle Band (SMA 20):	1175.87
Lower Band:	1106.18
%B:	0.7284
Band Width:	0.1185
Status:	Upper Half
Signal:	None


AUOPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	1219.86
Signal Identified On:	2026-01-13

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	-10.73
Signal Line:	-11.91
Histogram:	1.18
Trend:	Bullish
Momentum:	Weakening
Signal:	Bullish Crossover (Buy)

AUOPHARMA.NS Price




AUOPHARMA.NS MACD (12, 26, 9)



AUOPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.1185
ATR:	31.0571
Total Signals:	31
Signal 1:	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
Signal 2:	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)
Signal 3:	BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90)
Signal 4:	BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70)
Signal 5:	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10)

AUOPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	58.30
Current Volume:	8127226
Volume MA 20:	1188099
Bullish Divergences:	1
Bearish Divergences:	2
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

AUOPHARMA.NS RSI-Volume Divergence Analysis



AUROPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 28 Signals Detected

:

2025-12-31 [-]: Distribution Day



2026-01-07 [-]: Climax Volume (Churning)

2026-01-09 [-]: Distribution Day

2026-01-16 [-]: Distribution Day

2026-01-21 [+]: Selling Exhaustion (Bullish Div)

AUROPHARMA.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1207.7	2025-11-10
1 Day	DOWNTREND (Sell)	1219.86	1207.7	2026-01-13
15 Min	UPTREND (Buy)	1180.97	1198.9	2026-01-30

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	Bullish Crossover (Buy)
1 Day	Bullish	Weakening	Bullish Crossover (Buy)
15 Min	Bearish	Weakening	Bearish Crossover (Sell)

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)



AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - AUROPHARMA_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) Login / Sign up

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [AUROBINDO PHARMA LTD.](#)

Aurobindo Pharma Ltd. [ⓘ](#)

NSE: AUROPHARMA | BSE: 524804
Aurobindo Pharma Live Share Price Today, Share Analysis and Chart

Mid-range Performer [In 5 Starfolio Baskets](#)

1207.70 57.10 (4.96%) **8.9M** NSE+BSE Volume [High volume today](#)
NSE 30 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

[Preset Metrics](#) [Default](#)

Aurobindo Pharma Key Metrics

Market Capitalization > High in industry	70,143.4	PE TTM > Below Industry Median	20.5	PEG TTM > Negative PEG TTM	-4.6	Price to Book > Below Industry Median	Key Metrics
Institutional holding current Qtr % > High in industry	41.6	Revenue Growth Qtr YoY % > Below Industry Median	6.3	Operating Revenue growth TTM % > Below Industry Median	7.3	Net Profit Qtr Growth YoY % > Below Industry Median	DVM
Net Profit TTM Growth % > Negative Net Profit TTM Growth %	-4.4	Operating Profit Margin Qtr % > Above Industry Median	20.3	Operating Profit Margin TTM % > Above Industry Median	20.5	Plotroski Score > Below Industry Median	Price Chart
Rel Perf vs Nifty50 quarter% >	11.7	Rel Perf vs Sector quarter% >	13.9	ROE Annual % > Above Industry Median	10.7		Forecaster

All financials are in INR Cr and price data in INR

Durability & Valuation Scores

Free [SIGN IN](#) to see details

Mid-range Performer

Momentum Score [ⓘ](#)

55.1 /100

Technically Neutral

[FORECASTER](#) Please [SUBSCRIBE](#) to view forecast

These stocks have average quality, financial and technical momentum, indicating a mid range performer [View Similar](#) Embed DVM [X](#)

Trendlyne Snapshot - AUOPHARMA_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) [Search Stock, IPO, MF](#) [India](#) Login / Sign up

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [AUROBINDO PHARMA LTD.](#)

Aurobindo Pharma Ltd. [ⓘ](#)

NSE: AUOPHARMA | BSE: 524804 [Mid-range Performer](#) [In 5 Starfolio Baskets](#)

Download real time STOCK REPORT

1207.70 57.10 (4.96%) **8.9M** NSE+BSE Volume [High volume today](#) [NSE 30 Jan, 2026 3:31 PM \(IST\)](#)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Aurobindo Pharma - AUOPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1308, revenue growth forecast of 4.8%, and profit growth estimate of 4.4% for FY26, based on top 28 analyst calls.



Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

[Upgrade Now](#)[Sign in](#)

SAMPLE DATA BELOW

